Research programme: mesenchymal stem cells - Morphogen

Drug Profile

Research programme: mesenchymal stem cells - Morphogen

Alternative Names: Mesenchymal stem cells research programme - Morphogen

Latest Information Update: 05 May 2003

Price : $50

At a glance

  • Originator Morphogen Pharmaceuticals
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bone disorders

Most Recent Events

  • 05 May 2003 No development reported - Preclinical for Bone disorders in USA (unspecified route)
  • 17 Aug 2001 The programme is still in active development
  • 05 Feb 1998 Preclinical development for Bone disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top